Malaria: therapeutic implications of melatonin.
Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.
Srinivasan
Venkataramanujan
V
Sri Sathya Sai Medical Educational and Research Foundation, Prasanthi Nilayam, Coimbatore, India.
Spence
D Warren
DW
Moscovitch
Adam
A
Pandi-Perumal
Seithikurippu R
SR
Trakht
Ilya
I
Brown
Gregory M
GM
Cardinali
Daniel P
DP
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000378:metabolism*; D008550:Melatonin / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D008954:Models, Biological; D010963:Plasmodium falciparum / Q000187:drug effects / Q000254:growth & development*; D044094:Receptors, Melatonin / Q000037:antagonists & inhibitors; D014363:Tryptamines / Q000627:therapeutic use
D000962:Antimalarials; D044094:Receptors, Melatonin; D014363:Tryptamines; C057154:luzindole; D008550:Melatonin